Zsofia Sztupinszki, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
BRCA2 Protein | 4 | 2022 | 794 | 0.810 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1149 | 0.630 |
Why?
|
Sesquiterpenes | 2 | 2023 | 177 | 0.390 |
Why?
|
Mutation | 6 | 2021 | 29786 | 0.360 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2023 | 2245 | 0.330 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.250 |
Why?
|
Neoplasms | 7 | 2024 | 21683 | 0.250 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4838 | 0.240 |
Why?
|
DNA Repair | 6 | 2023 | 2046 | 0.230 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 11124 | 0.230 |
Why?
|
Receptors, Formyl Peptide | 2 | 2021 | 145 | 0.230 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3586 | 0.230 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 112 | 0.220 |
Why?
|
Templates, Genetic | 1 | 2021 | 211 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 203 | 0.190 |
Why?
|
Viral Tail Proteins | 1 | 2020 | 4 | 0.190 |
Why?
|
Poly I-C | 1 | 2020 | 115 | 0.190 |
Why?
|
Replication Protein A | 1 | 2020 | 52 | 0.180 |
Why?
|
Toll-Like Receptor 3 | 1 | 2020 | 91 | 0.180 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2023 | 548 | 0.180 |
Why?
|
Cytological Techniques | 1 | 2021 | 219 | 0.180 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1038 | 0.170 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 648 | 0.160 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2022 | 1366 | 0.150 |
Why?
|
Bacteriophages | 1 | 2020 | 356 | 0.150 |
Why?
|
DNA Damage | 3 | 2023 | 2432 | 0.150 |
Why?
|
Gene Amplification | 1 | 2021 | 1063 | 0.150 |
Why?
|
DNA Replication | 2 | 2022 | 1399 | 0.140 |
Why?
|
Antigen Presentation | 1 | 2022 | 1284 | 0.140 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13695 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2022 | 1861 | 0.120 |
Why?
|
Cholesterol | 1 | 2023 | 2917 | 0.120 |
Why?
|
Ligands | 1 | 2020 | 3282 | 0.110 |
Why?
|
Artifacts | 1 | 2021 | 1904 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2915 | 0.110 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4186 | 0.110 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1988 | 0.110 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 2 | 2023 | 105 | 0.100 |
Why?
|
Immunotherapy | 3 | 2023 | 4445 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2942 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4803 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2303 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.080 |
Why?
|
Genes, BRCA2 | 2 | 2023 | 618 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3143 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2734 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2023 | 15519 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4262 | 0.070 |
Why?
|
Models, Statistical | 1 | 2021 | 5102 | 0.070 |
Why?
|
Humans | 22 | 2024 | 744343 | 0.070 |
Why?
|
Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
Janus Kinase 1 | 1 | 2022 | 104 | 0.050 |
Why?
|
Ribonuclease H | 1 | 2022 | 45 | 0.050 |
Why?
|
DNA Contamination | 1 | 2021 | 19 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 440 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6773 | 0.050 |
Why?
|
Normal Distribution | 1 | 2021 | 280 | 0.050 |
Why?
|
Nucleotides | 1 | 2023 | 464 | 0.050 |
Why?
|
Acetylation | 1 | 2023 | 1085 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2021 | 16689 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2024 | 1369 | 0.050 |
Why?
|
H-2 Antigens | 1 | 2020 | 366 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2020 | 189 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 376 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29063 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3521 | 0.040 |
Why?
|
Hydroxyurea | 1 | 2020 | 290 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2023 | 1060 | 0.040 |
Why?
|
Biological Transport | 1 | 2023 | 2118 | 0.040 |
Why?
|
Cross Reactions | 1 | 2020 | 841 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 509 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2021 | 1341 | 0.040 |
Why?
|
Organ Specificity | 1 | 2021 | 2008 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 627 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2021 | 1758 | 0.030 |
Why?
|
Ubiquitination | 1 | 2020 | 1012 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1265 | 0.030 |
Why?
|
DNA Helicases | 1 | 2020 | 859 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2242 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1662 | 0.030 |
Why?
|
Feces | 1 | 2020 | 1401 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2021 | 1431 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1692 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3206 | 0.030 |
Why?
|
Epitopes | 1 | 2020 | 2571 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6314 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1580 | 0.030 |
Why?
|
Alleles | 1 | 2023 | 6933 | 0.030 |
Why?
|
Cell Cycle | 1 | 2020 | 2967 | 0.030 |
Why?
|
Vaccination | 1 | 2024 | 3278 | 0.030 |
Why?
|
Chromatin | 1 | 2023 | 2934 | 0.030 |
Why?
|
Regression Analysis | 1 | 2021 | 6459 | 0.020 |
Why?
|
Male | 4 | 2023 | 350118 | 0.020 |
Why?
|
Models, Genetic | 1 | 2021 | 3494 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3505 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 5882 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2023 | 4665 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2727 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81183 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8436 | 0.020 |
Why?
|
Proteomics | 1 | 2021 | 3638 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4420 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9734 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2023 | 5172 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
Female | 2 | 2021 | 380194 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6544 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5535 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5720 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9438 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2021 | 7880 | 0.020 |
Why?
|
Animals | 3 | 2021 | 168757 | 0.020 |
Why?
|
Phenotype | 1 | 2021 | 16365 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19905 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9274 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18029 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13881 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2022 | 63114 | 0.010 |
Why?
|